Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
CAPR Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Neutral11-14
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Neutral8-9
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
Positive5-14
The earnings call highlights significant progress in product development, strategic partnerships, and financial performance. Positive interim results in the Phase III trial, increased revenue, and reduced net loss are notable. The Q&A reveals confidence in regulatory strategies and strong safety profiles, despite some uncertainties. The potential for milestone payments and global expansion, along with a strong cash position, supports a positive outlook. However, increased R&D expenses and lack of specific guidance on milestone triggers and partnerships temper enthusiasm slightly. Overall, the stock is likely to see a positive movement in the short term.
CAPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
